Printer Friendly

Novo Nordisk A/S gets EU approval for blood disorders drug.

NORDIC BUSINESS REPORT-20 February 2004-Novo Nordisk A/S gets EU approval for blood disorders drug(C)1994-2004 M2 COMMUNICATIONS LTD

Danish pharmaceutical company Novo Nordisk A/S has received approval from the European Commission for its NovoSeven drug for the treatment of two rare blood disorders.

NovoSeven has been approved for the control of bleeding in patients with factor VII deficiency and also for patients suffering from Glanzmann's thrombasthenia.

NovoSeven is the first genetically engineered or recombinant product that has been licensed to treat these disorders, Novo Nordisk said.

((Comments on this story may be sent to

COPYRIGHT 2004 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Geographic Code:4EUDE
Date:Feb 20, 2004
Previous Article:Securitas signs final agreement to acquire Pengar i Sverige AB.
Next Article:Decline in number of asylum applicants in Norway.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters